Lyophilized Recombinant Human Brain Natriuretic Peptide and Sodium Nitroprusside on Acute Decompensated Heart Failure and Influence on the CTnI NT-ProBNP and Hs-CRP Levels
ZHANG Shirui, ZHU Li, YUAN Yuling, et al
The Affiliated Minda Hospital of Hubei University of Nationalities, Hubei Enshi 445000, China
Abstract：Objective: To analyze and compare the clinical effect on acute decompensated heart failure (ADHF) between lyophilized recombinant human brain natriuretic peptide (Lrh-BNP) and sodium nitroprusside (SNP) and influence on the plasma cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP) and hypersensitivity C reactive protein (hs-CRP) levels.Methods: 98 patients with ADHF admitted to our hospital from May 2015 to May 2018 were selected and evenly divided into two groups with simple random number table method.Lrh-BNP group was treated with Lrh-BNP while SNP group was treated with SNP.The clinical effect, changes of heart function indexes and plasma cTnI, NT-proBNP and hs-CRP levels before and after treatment as well as the incidence of adverse reactions were compared between the two groups.Results: The overall effective rate of Lrh-BNP group after treatment for 7 days was evidently higher than that of SNP group (P<0.05).The LVEF values of both groups 7d after treatment were significantly increased as compared with those before treatment (P<0.01), and the LVEDD, LVESD values, plasma cTnI, NT-proBNP and hs-CRP levels were significantly decreased as compared with those before treatment (P<0.05).The LVEF value of Lrh-BNP group was higher than that of the SNP group (P<0.05), while the LVEDD, LVESD values, plasma cTnI, NT-proBNP and hs-CRP levels of Lrh-BNP group were obviously lower than those of the control group(P<0.01).No difference was found between the two groups in the incidence of adverse reactions(P>0.05).Conclusion: Compared with SNP, Lrh-BNP could obviously enhance the clinical efficacy in the treatment of ADHF, improve the cardiac function, which might be related to decrease the plasma levels of cTnI, NT-proBNP and hs-CRP.
[1] 靳嘉麟,李岩,李天力,等.中药制剂干预慢性心力衰竭急性失代偿病人临床疗效与安全性的系统评价[J].中西医结合心脑血管病杂志,2019,17(19):2891~2900. [2] 王鲲.新活素与硝普钠联合治疗慢性心力衰竭[J].武警后勤学院学报(医学版),2018,27(1):27~29. [3] 张艳利,于海侠,郭金朋,等.新活素对心肺复苏后心力衰竭患者心功能及血清IL-6影响的研究[J].临床急诊杂志,2020,21(3):209~211. [4] 及孟,李光智,余洪,等.破格救心汤联合重组人脑利钠肽对急性心力衰竭患者心功能及血清BNP、CK-MB和cTnI水平的影响[J].中国中医急症,2019,28(9):1524~1527. [5] 李明霞,李雪芬.运动康复对慢性心力衰竭患者血清NT-proBNP、hscTnT水平及心功能的影响[J].心血管康复医学杂志,2019,28(5):576~579. [6] Kenneth C. Bilchick, Nathaniel Chishinga, Alex M. Parker,et al. Plasma volume and renal function predict six-month survival after hospitalization for acute decompensated heart failure[J]. Cardiorenal Medicine, 2018, 8(1):61~70. [7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98~122. [8] 林文婷,曾敏,何扬利,等.托拉塞米联合阿托伐他汀对COPD伴急性心力衰竭病人血清炎症因子、基质金属蛋白酶水平的影响[J].中西医结合心脑血管病杂志,2019,17(15):2316~2320. [9] 齐芳,刘冰.硝普钠联合多巴胺治疗顽固性心衰的临床效果观察[J].中国实用医药,2020,15(4):92~93. [10] van Kranendonk KR, Treurniet KM, Boers AMM,et al. Hemorrhagic transformation is associated with poor functional outcome in patients with acute ischemic stroke due to a large vessel occlusion[J]. Journal of Neurointerventional Surgery, 2019, 11(5):464.
2020, Vol. 26 
冀公网安备13080202000677号